Sanofi S.A. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/14/2026)
| Balance Sheet | Total Assets | 126,805,000,000.00 | ROE | 56.29 % |
| Balance Sheet | Total Equity | 71,376,000,000.00 | ROA | 6.16 % |
| Cashflow | Capital Expenditures | -3,538,000,000.00 | P/FCF | 12.00 |
| Cashflow | Free Cash Flow | 7,212,000,256.00 | – | – |
| Cashflow | Operating Cash Flow | 10,750,000,000.00 | P/CF | 8.05 |
| Income | Earnings per Share (diluted) | 6.47 | Div. Yield | 5.75 % |
| Income | Net Income | 7,813,000,000.00 | P/E | 11.08 |
| Income | Shares Outstanding | 1,207,640,000.00 | P/B | 1.21 |
| Income | Total Revenue | 46,716,000,000.00 | P/S | 1.85 |
Ratios calculated on: 10/14/2026
Company Description
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Company's principal activities. Under the Company's Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.sanofi.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more